查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930028

鸦片类药物使用障碍（OUD）市场规模、占有率、成长及全球产业分析：依药物类别、给药途径、通路和地区划分的洞察与预测（2025-2034）

Opioid Use Disorder Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 129 Pages | 商品交期: 请询问到货日

价格

鸦片类药物使用障碍（OUD）市场成长驱动因素

到2025年，全球鸦片类药物使用障碍（OUD）市场规模达到 39.2亿美元，预计2026年将达到 42.6亿美元，到2034年将进一步成长至 92.7亿美元。市场成长的主要驱动因素包括鸦片类药物成瘾的日益普遍、政府介入计画的扩展以及药物辅助治疗方案的日益普及。2025年，北美将以 77.59%的市场占有率主导全球市场，这主要得益于该地区较高的疾病盛行率和强大的公共医疗保健资金投入。

鸦片类药物使用疾患是一种慢性疾病，其特征是儘管存在不良后果，仍会强迫性地使用鸦片类药物。 获准用于治疗的药物，包括Buprenorphine、Methadone和Naltrexone，均作为受监管的疗法获得许可，用于缓解戒断症状、降低復发风险并减少过量用药死亡率。慢性疾病患者对鸦片类止痛药的处方量不断上升，持续增加成瘾风险，推动了对长期治疗方案的需求。

市场成长驱动因素

鸦片类药物成瘾的上升趋势仍然是鸦片类药物使用障碍（OUD）市场的主要成长因素。与癌症、骨科疾病和术后復原相关的慢性疼痛通常需要使用鸦片类镇痛药，这增加了长期成瘾的风险。全球药物使用统计资料显示，鸦片类药物暴露持续增加，导致 OUD 诊断和治疗需求不断上升。

2021年，美国约有 270万人受到 OUD 的影响，药物辅助治疗计画的使用率显着提高。政府增加对药物滥用预防和治疗计画的支出，也有助于提高鸦片类药物使用障碍（OUD）药物的可及性和偿付率。资助计画扩大了鸦片类药物治疗方案，并增加了门诊治疗服务，特别是注射长效製剂。

市场限制

OUD 药物的副作用可能会限制治疗顺从性和市场成长。常见副作用包括噁心、便秘、呼吸抑制、肌肉疼痛和心理症状。监管机构对口服Buprenorphine製剂可能引起的牙科併发症发出的警告也影响了患者的信心。安全隐患可能导致治疗启动延迟和长期依从性降低，尤其是在已有疾病的患者中。

此外，与药物滥用障碍相关的社会污名仍然是及时就医的障碍，尤其是在发展中地区，这限制了诊断率并降低了治疗接受率。

市场趋势

一个关键的市场趋势是Buprenorphine透皮製剂和长效注射剂的日益普及，这些製剂透过减少每日用药次数来提高患者的用药依从性。这些製剂能够持续释放药物并降低復发风险，因此适用于长期门诊治疗。对缓释和长效注射剂的投资不断成长，为需要持续鸦片类药物成瘾管理的患者拓展治疗选择。

数位治疗平台和远距医疗的整合也日益受到关注，它们支持药物治疗的同时进行行为咨询，并促进患者参与復健计画。

细分市场分析

依药物类别

市场细分为Buprenorphine、Methadone和Naltrexone。由于临床接受度高且拥有多种品牌製剂，Buprenorphine类药物在2026年占据了83.24%的市场占有率，成为市场主导。 SUBLOCADE、SUBOXONE和ZUBSOLV等产品支援长期治疗策略，并在已开发市场广泛应用。

由于仿製药日益普及以及临床分发受到监管限制，Methadone的市场占有率下降。Naltrexone的使用仍然有限，原因在于其製剂种类有限，且医生将其作为一线治疗药物的意愿不高。

依给药途径

根据给药途径，市场分为口服和注射给药。肠外给药领域，由于长效注射剂的广泛应用（可稳定药物暴露并降低滥用风险），预计到2026年将占市场占有率的84.65%。口服製剂因其便利性和门诊治疗的灵活性而持续稳定成长。

依通路划分

通路包括院内药房、零售药房和线上药房。由于注射疗法通常透过监督治疗方案进行，院内药房占据主导地位，预计到2026年将占 46.19%的市场占有率。零售药房在口服药物的配发方面仍然发挥着重要作用，而线上药局则因其便利性和隐私性优势而不断扩张。

区域展望

北美预计仍将是最大的区域市场，到2025年市场规模将达到30.4亿美元，这主要得益于该地区较高的成瘾率和完善的治疗体系。美国市场预计到2026年将达到30.4亿美元，主要得益于强而有力的偿付政策和联邦资助计画。

欧洲由于Buprenorphine疗法的日益普及，因此保持第二的位置。截至2026年，英国市场规模将达9,000万美元，德国将达到7,000万美元。亚太地区由于医疗保健支出增加和宣传活动的开展，呈现出强劲的成长动能。到2026年，中国市场规模将达到1亿美元，日本将达到8,000万美元，印度将达到5,000万美元。由于诊断率上升和医疗保健投资增加，拉丁美洲和中东及非洲地区的市场持续成长。

报告涵盖范围

本报告详细分析了2025年、2026年和2034年的市场规模和价值，并依药物类别、给药途径和通路进行了细分。本研究涵盖北美、欧洲、亚太地区和世界其他地区的区域市场评估，并提供了主要经济体的国别市场价值。本研究检视了塑造全球鸦片类药物使用障碍治疗格局的产业发展、监管审批、产品上市、合作关係和临床创新。 Buprenorphine仍将是领先的药物类别，到2026年将占据83.24%的市场占有率，这主要得益于多种品牌製剂的供应以及患者对长效注射剂和透皮製剂日益成长的偏好，这些製剂能够提高治疗依从性并降低復发风险。到2026年，肠外给药途径将占84.65%的市场占有率，这凸显了临床上对在结构化治疗环境中进行监督下的长效治疗的偏好。同时，医院药局预计到2026年将维持46.19%的市场占有率，这反映了鸦片类药物治疗计画和住院治疗机构在药物管理方面发挥的核心作用。

依地区划分，北美地区凭藉较高的诊断率和完善的治疗基础设施继续引领市场。同时，欧洲的Buprenorphine类药物产品获准数量不断增加，且其应用日益广泛。亚太地区正崛起为高成长地区，这主要得益于医疗保健支出的成长、成瘾治疗服务可及性的提高以及中国、日本和印度等国家扩大的公众意识宣传活动。拉丁美洲以及中东和非洲地区也正逐步扩张，这得益于各国政府对医疗保健和药物滥用障碍问题的日益重视。

药物递送平台、缓释製剂和数位治疗模式的创新持续推动着竞争格局的发展。 Indivior、Alkermes 和 Orexo 等市场领导者不断透过研发投入、监管审批和策略联盟来强化其产品组合。同时，其他製造商则专注于缓释技术和解决方案，以提高患者的依从性。製剂科学的持续进步，加上有利的政策框架和不断扩大的治疗覆盖范围，预计将支持全球医疗和门诊领域的长期持续成长。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 关键洞察

  • 产品线分析：主要产品
  • 新产品发布
  • 鸦片类药物使用疾患统计：主要国家和地区
  • 产业趋势，包括併购和合作
  • COVID-19 对鸦片类药物使用障碍（OUD）市场的影响

第5章 全球鸦片类药物使用障碍鸦片类药物使用障碍（OUD）市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区

第6章 北美和全球鸦片类药物使用情况鸦片类药物使用障碍（OUD）市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依国家划分
    • 美国
    • 加拿大

第7章 欧洲鸦片类药物使用障碍（OUD）市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依国家和地区划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 北欧国家
    • 其他国家/地区欧洲

第8章 亚太地区鸦片类药物使用障碍（OUD）市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依国家和地区划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 世界其他地区鸦片类药物使用障碍（OUD）市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路
    • 医院药房
    • 零售药房
    • 线上药房

第10章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Indivior PLC
    • Alkermes
    • Orexo US, Inc.
    • Titan Pharmaceuticals Inc.
    • Mallinckrodt
    • BioDelivery Sciences International Inc.
    • Viatris（Mylan N.V.）
    • Hikma Pharmaceuticals
    • Camurus
    • Braeburn Inc.
Product Code: FBI102674

Growth Factors of Opioid Use Disorder (OUD) Market

The global Opioid Use Disorder (OUD) market size was valued at USD 3.92 billion in 2025 and is projected to reach USD 4.26 billion in 2026, further expanding to USD 9.27 billion by 2034. Market expansion is driven by increasing opioid addiction prevalence, rising government intervention programs, and growing availability of medication-assisted treatment options. In 2025, North America dominated the global market with a share of 77.59%, supported by high disease prevalence and strong public healthcare funding.

Opioid Use Disorder is a chronic medical condition characterized by compulsive opioid use despite harmful consequences. Approved medications for treatment include buprenorphine, methadone, and naltrexone, which are regulated therapies authorized for reducing withdrawal symptoms, relapse risk, and overdose mortality. Rising prescription rates for opioid-based pain medications for chronic diseases continue to contribute to dependency risks, thereby increasing the demand for long-term treatment solutions.

Market Growth Factors

The growing incidence of opioid addiction remains a major growth driver for the OUD market. Chronic pain conditions related to cancer, orthopedic disorders, and post-surgical recovery often require opioid-based analgesics, which increase long-term dependency risks. Global drug usage statistics indicate a steady rise in opioid exposure, contributing to higher OUD diagnosis rates and treatment demand.

In the U.S., approximately 2.7 million individuals were affected by OUD in 2021, driving strong utilization of medication-assisted treatment programs. Increased government spending on substance abuse prevention and treatment programs is also supporting drug accessibility and insurance reimbursement for OUD medications. Funding initiatives are expanding opioid treatment programs and increasing availability of clinic-based therapies, especially injectable long-acting formulations.

Market Restraints

Adverse effects associated with OUD medications may restrict treatment adherence and market growth. Common side effects include nausea, constipation, respiratory depression, muscle pain, and psychological symptoms. Regulatory warnings regarding dental complications associated with buprenorphine oral formulations have also impacted patient confidence. Safety concerns may delay therapy initiation or reduce long-term compliance, particularly in patients with pre-existing medical conditions.

In addition, social stigma related to substance abuse disorders remains a barrier to seeking timely medical care, especially in developing regions, limiting diagnosis rates and reducing treatment penetration.

Market Trends

A key trend in the market is the increasing adoption of buprenorphine transdermal and long-acting injectable therapies, which improve compliance by reducing daily dosing requirements. These formulations offer steady drug delivery and lower relapse risks, making them suitable for long-term outpatient management. Growing investments in extended-release formulations and depot injections are expanding therapeutic options for patients requiring continuous opioid dependence control.

Digital therapy platforms and telemedicine integration are also gaining attention, supporting behavioral counseling alongside pharmacological treatment and improving patient engagement in recovery programs.

Segmentation Analysis

By Drug Class

The market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment dominated the market with a share of 83.24% in 2026, driven by high clinical acceptance and multiple branded drug formulations. Products such as SUBLOCADE, SUBOXONE, and ZUBSOLV support long-term treatment strategies and are widely prescribed in developed markets.

Methadone holds a smaller share due to increased generic availability and regulatory restrictions on clinic-based distribution. Naltrexone adoption remains limited due to fewer available formulations and lower physician preference for first-line therapy.

By Route of Administration

Based on route of administration, the market is categorized into oral and parenteral. The parenteral segment accounted for 84.65% market share in 2026, supported by widespread use of injectable depot therapies that ensure consistent drug exposure and reduce misuse risks. Oral formulations continue to grow steadily due to patient convenience and outpatient treatment flexibility.

By Distribution Channel

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated with a 46.19% share in 2026, as injectable therapies are typically administered through supervised treatment programs. Retail pharmacies remain critical for oral medication dispensing, while online pharmacies are expanding due to convenience and privacy benefits.

Regional Outlook

North America remained the largest regional market with USD 3.04 billion in 2025, supported by high addiction prevalence and extensive treatment infrastructure. The U.S. market reached USD 3.04 billion by 2026, driven by strong reimbursement policies and federal funding programs.

Europe ranks second, supported by rising adoption of buprenorphine therapies. By 2026, the U.K. market was valued at USD 0.09 billion, while Germany reached USD 0.07 billion. Asia Pacific shows strong growth momentum, with increasing healthcare spending and awareness campaigns. By 2026, China reached USD 0.10 billion, Japan USD 0.08 billion, and India USD 0.05 billion. Latin America and Middle East & Africa continue to expand due to rising diagnosis rates and healthcare investments.

Competitive Landscape

The market is dominated by Indivior PLC, Alkermes, and Orexo AB, which together hold a significant market share through extensive buprenorphine and naltrexone portfolios. These companies focus on long-acting injectable therapies, improved delivery platforms, and regulatory approvals to expand treatment accessibility.

Other notable players include Titan Pharmaceuticals, Mallinckrodt Pharmaceuticals, Viatris, Hikma Pharmaceuticals, and Camurus, which are investing in extended-release technologies and novel drug delivery systems to improve patient adherence.

Report Coverage

The report provides detailed analysis of market size and value for 2025, 2026, and 2034, along with segmentation by drug class, route of administration, and distribution channel. It includes regional market evaluation across North America, Europe, Asia Pacific, and the rest of the world, with country-level market values for major economies. The study examines industry developments, regulatory approvals, product launches, partnerships, and clinical innovation trends shaping the global opioid use disorder treatment landscape.

Conclusion

The Opioid Use Disorder (OUD) market is positioned for strong expansion from USD 3.92 billion in 2025 to USD 4.26 billion in 2026, reaching USD 9.27 billion by 2034, reflecting the growing global burden of opioid dependency and the rising demand for structured, medication-assisted treatment programs. High disease prevalence, particularly in North America with a 77.59% market share in 2025, continues to shape treatment adoption patterns, supported by strong reimbursement frameworks and large-scale government funding initiatives focused on substance abuse prevention and recovery.

Buprenorphine remains the dominant drug class, accounting for 83.24% market share in 2026, driven by the availability of multiple branded formulations and increasing preference for long-acting injectable and transdermal delivery systems that improve treatment adherence and reduce relapse risks. The dominance of the parenteral route with 84.65% share in 2026 highlights the clinical preference for supervised, long-acting therapies in structured treatment settings, while hospital pharmacies maintaining 46.19% share in 2026 reflects the central role of opioid treatment programs and inpatient care facilities in administering these medications.

Regionally, North America continues to lead due to high diagnosis rates and well-established treatment infrastructure, while Europe benefits from expanding product approvals and strong adoption of buprenorphine-based therapies. Asia Pacific is emerging as a high-growth region due to increasing healthcare expenditure, improving access to addiction treatment services, and rising public awareness initiatives in countries such as China, Japan, and India. Latin America and the Middle East & Africa are also gradually expanding as healthcare access and policy attention toward substance abuse disorders increase.

Competitive dynamics remain driven by innovation in drug delivery platforms, long-acting formulations, and digital treatment support models. Market leaders such as Indivior, Alkermes, and Orexo continue to strengthen their portfolios through R&D investments, regulatory approvals, and strategic collaborations, while other manufacturers focus on extended-release technologies and improved patient compliance solutions. Ongoing advancements in formulation science, coupled with supportive policy frameworks and expanding treatment coverage, are expected to sustain long-term growth across institutional and outpatient treatment settings worldwide.

Segmentation By Drug Class

  • Buprenorphine
  • Methadone
  • Naltrexone

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

By Region

  • North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
    • Japan
    • China
    • India
    • Australia
    • South East Asia
    • Rest of Asia Pacific
  • Rest of the World (By Drug Class, By Route of Administration, By Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, Key Products
  • 4.2. New Product Launches
  • 4.3. Statistics of Opioid Use Disorder by Key Countries/Region
  • 4.4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of COVID-19 on Opioid Use Disorder (OUD) Market

5. Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Buprenorphine
    • 5.1.2. Methadone
    • 5.1.3. Naltrexone
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals Pharmacies
    • 5.3.2. Retail Pharmacies & Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Buprenorphine
    • 6.1.2. Methadone
    • 6.1.3. Naltrexone
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals Pharmacies
    • 6.3.2. Retail Pharmacies & Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Buprenorphine
    • 7.1.2. Methadone
    • 7.1.3. Naltrexone
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals Pharmacies
    • 7.3.2. Retail Pharmacies & Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Buprenorphine
    • 8.1.2. Methadone
    • 8.1.3. Naltrexone
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies & Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Buprenorphine
    • 9.1.2. Methadone
    • 9.1.3. Naltrexone
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Retail Pharmacies & Stores
    • 9.3.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Indivior PLC
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT analysis
      • 10.2.1.4. Recent developments
      • 10.2.1.5. strategies
      • 10.2.1.6. financials (based on availability)
    • 10.2.2. Alkermes
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT analysis
      • 10.2.2.4. Recent developments
      • 10.2.2.5. strategies
      • 10.2.2.6. financials (based on availability)
    • 10.2.3. Orexo US, Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT analysis
      • 10.2.3.4. Recent developments
      • 10.2.3.5. strategies
      • 10.2.3.6. financials (based on availability)
    • 10.2.4. Titan Pharmaceuticals Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT analysis
      • 10.2.4.4. Recent developments
      • 10.2.4.5. strategies
      • 10.2.4.6. financials (based on availability)
    • 10.2.5. Mallinckrodt
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT analysis
      • 10.2.5.4. Recent developments
      • 10.2.5.5. strategies
      • 10.2.5.6. financials (based on availability)
    • 10.2.6. BioDelivery Sciences International Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT analysis
      • 10.2.6.4. Recent developments
      • 10.2.6.5. strategies
      • 10.2.6.6. financials (based on availability)
    • 10.2.7. Viatris (Mylan N.V.)
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT analysis
      • 10.2.7.4. Recent developments
      • 10.2.7.5. strategies
      • 10.2.7.6. financials (based on availability)
    • 10.2.8. Hikma Pharmaceuticals
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT analysis
      • 10.2.8.4. Recent developments
      • 10.2.8.5. strategies
      • 10.2.8.6. financials (based on availability)
    • 10.2.9. Camurus
      • 10.2.9.1. Overview
      • 10.2.9.2. Products
      • 10.2.9.3. SWOT analysis
      • 10.2.9.4. Recent developments
      • 10.2.9.5. strategies
      • 10.2.9.6. financials (based on availability)
    • 10.2.10. Braeburn Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products
      • 10.2.10.3. SWOT analysis
      • 10.2.10.4. Recent developments
      • 10.2.10.5. strategies
      • 10.2.10.6. financials (based on availability)

List of Tables

  • Table 1: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Opioid Use Disorder (OUD) Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Opioid Use Disorder (OUD) Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 8: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 10: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 12: North America Opioid Use Disorder (OUD) Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Opioid Use Disorder (OUD) Market Value Share (%), By Country, 2023
  • Figure 14: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 16: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 18: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 20: Europe Opioid Use Disorder (OUD) Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Opioid Use Disorder (OUD) Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 22: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 24: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 26: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 28: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 30: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 32: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 34: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 36: Global Opioid Use Disorder (OUD) Market Share (%), By Company, 2023